<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sulfadiazine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sulfadiazine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sulfadiazine: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11873" href="/d/html/11873.html" rel="external">see "Sulfadiazine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12814" href="/d/html/12814.html" rel="external">see "Sulfadiazine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F223802"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Sulfonamide Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F223778"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b>
<b>Oral:</b> 2 to 4 g/day in 3 to 6 divided doses.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ac084ce2-0eae-4ea8-a713-1553b024829c">Rheumatic fever prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatic fever prophylaxis:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">≤27 kg: 500 mg once daily (AHA [Gerber 2009]).</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;27 kg: 1 g once daily (AHA [Gerber 2009]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d30e1f79-4cc9-4f83-8590-fee942eaa71a">
<i>Toxoplasma gondii</i> encephalitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Toxoplasma gondii </i>encephalitis: Note:</b> Patients receiving sulfadiazine and pyrimethamine for treatment or suppression of toxoplasmosis do not require additional pneumocystis prophylaxis (HHS [OI adult 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment</i>
<i>of acute infection</i> (duration of therapy: ≥6 weeks): <b>Oral: </b>1 g (&lt;60 kg) or 1.5 g (≥60 kg) every 6 hours in combination with pyrimethamine plus leucovorin calcium (preferred) <b>or </b>alternatively, in combination with atovaquone (HHS [OI adult 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic maintenance</i>: <b>Oral:</b> 2 to 4 g/day in 2 to 4 divided doses in combination with pyrimethamine and leucovorin calcium (preferred) <b>or</b> alternatively, in combination with atovaquone; may discontinue if successfully completed initial treatment, remain asymptomatic of signs/symptoms of <i>T. gondii</i> encephalitis, and CD4 count is &gt;200 cells/mm<sup>3</sup> for &gt;6 months in response to antiretroviral therapy (HHS [OI adult 2021]).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F55909009"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F55909010"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F223779"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F223791"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12814" href="/d/html/12814.html" rel="external">see "Sulfadiazine: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Infants ≥2 months, Children, and Adolescents: Oral: 120 to 150 mg/kg/day in divided doses 4 to 6 times daily; maximum daily dose: 6 g/<b>day</b> (<i>Red Book </i>[AAP 2021]; manufacturer's labeling).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e41af1d-f57a-4044-bfa3-84beb015adc1">Toxoplasmosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxoplasmosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Congenital (regardless of HIV status):</i> Infants: Oral: 50 mg/kg/dose every 12 hours for 12 months in combination with pyrimethamine and leucovorin (HHS [pediatric OI 2021]; <i>Red Book </i>[AAP 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acquired (including encephalitis):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HIV-exposed/-infected: <b>Note: </b>Use in combination with pyrimethamine and leucovorin for ≥6 weeks, followed by chronic maintenance therapy (secondary prophylaxis); longer duration may be required if incomplete response or extensive disease (HHS [adult OI 2021]; HHS [pediatric OI 2021]).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥2 months and Children: Oral: 25 to 50 mg/kg/dose every 6 hours; maximum dose: 1,500 mg/dose (HHS [pediatric OI 2021]).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents (HHS [adult OI 2021]):</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;60 kg: 1,000 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">≥60 kg: 1,500 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Non-HIV-exposed/-infected patients: Infants ≥2 months, Children, and Adolescents: Oral: 25 to 50 mg/kg/dose every 6 hours; maximum dose: 1,500 mg/dose; use in combination with pyrimethamine and leucovorin. Continue for ≥2 weeks after resolution of illness in immunocompetent patients and ≥4 to 6 weeks after resolution of illness in immunocompromised patients; longer duration may be necessary based on patient response (Bradley 2021; CDC 2020; <i>Red Book </i>[AAP 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chorioretinitis</i>
<i>: </i>
<b>Note: </b>Use in combination with pyrimethamine and leucovorin for ≥6 weeks, followed by chronic maintenance therapy (secondary prophylaxis); longer duration may be required if incomplete response or extensive disease (HHS [adult OI 2021]; HHS [pediatric OI 2021]).</p>
<p style="text-indent:-2em;margin-left:6em;">HIV-exposed/-infected:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥2 months and Children: Oral: 25 to 50 mg/kg/dose every 6 hours; maximum dose: 1,500 mg/dose (HHS [pediatric OI 2021]).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents (HHS [adult OI 2021]):</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;60 kg: 1,000 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">≥60 kg: 1,500 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Non-HIV-exposed/-infected: Children and Adolescents: Oral: Loading dose: 75 mg/kg once; followed by 50 mg/kg/dose every 12 hours starting 12 hours after loading dose; maximum daily dose: 4,000 mg/<b>day</b>. Use in combination with pyrimethamine and leucovorin for 1 to 2 weeks after resolution of clinical manifestations; usual duration 4 to 6 weeks; however, prolonged therapy (up to 3 months) may be necessary (<i>Red Book </i>[AAP 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic </i>
<i>maintenance therapy (secondary prevention): </i>
<b>Note:</b> Use in combination with pyrimethamine and leucovorin. May consider discontinuation when asymptomatic, the patient has completed ≥6 months of stable antiretroviral therapy with CD4 percentage ≥15% (or CD4 count is &gt;200 cells/mm<sup>3</sup> for ages ≥6 years) for &gt;6 consecutive months.</p>
<p style="text-indent:-2em;margin-left:6em;">HIV-exposed/-infected:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥2 months and Children: Oral: 85 to 120 mg/kg/day in 2 to 4 divided doses; maximum daily dose: 4,000 mg/<b>day</b> (HHS [pediatric OI 2021]).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 2,000 to 4,000 mg/day in 2 to 4 divided doses (HHS [adult OI 2021]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="414a6e47-e117-4eae-888a-00ccd94a37a7">Rheumatic fever; secondary prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatic fever; secondary prevention</b> (AHA [Gerber 2009]; <i>Red Book</i> [AAP 2021):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight ≤27 kg: Oral: 500 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &gt;27 kg: Oral: 1,000 mg once daily.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51160221"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51160222"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F223752"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypersensitivity myocarditis, polyarteritis nodosa</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, exfoliative dermatitis, pruritus, skin photosensitivity, skin rash, Stevens-Johnson syndrome (Velter 2018), toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (Craft 1977)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea, pancreatitis, stomatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Crystalluria (de Sequera 1996), obstructive uropathy (Kabha 2016), toxic nephrosis (with anuria and oliguria) (Craft 1977)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, hemolytic anemia, hypoprothrombinemia, leukopenia, methemoglobinemia, purpuric disease, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury (including fulminant hepatitis, hepatitis, hepatorenal syndrome, increased liver enzymes, jaundice) (Khalili 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Monge-Ortega 2018), hypersensitivity reaction (McLeod 2006), nonimmune anaphylaxis, serum sickness</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, chills, depression, drug fever, hallucination, headache, insomnia, peripheral neuritis, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, lupus erythematosus (Hogan 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctival injection, injected sclera, periorbital edema</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (de Sequera 1996), nephrolithiasis (McGettigan 2012), nephrotoxicity (Becker 1996), renal failure syndrome (Marques 1992)</p></div>
<div class="block coi drugH1Div" id="F223764"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to sulfonamides or any component of the formulation; infants &lt;2 months of age unless indicated for the treatment of congenital toxoplasmosis; pregnancy (at term); breastfeeding.</p></div>
<div class="block war drugH1Div" id="F223749"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood dyscrasias: Fatalities associated with severe reactions including agranulocytosis, aplastic anemia and other blood dyscrasias have occurred; discontinue use at first sign of rash or signs of serious adverse reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Fatalities associated with severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have occurred; discontinue use at first sign of rash.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic necrosis: Fatalities associated with hepatic necrosis have occurred; discontinue use at first sign of rash.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide (“sulfa”) allergy: Traditionally, concerns for cross-reactivity have extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur, or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides and antibiotic sulfonamides. A nonantibiotic sulfonamide compound which contains the arylamine structure and therefore may cross-react with antibiotic sulfonamides is sulfasalazine (Zawodniak 2010). T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Allergies/asthma: Use with caution in patients with allergies or asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glucose 6-phosphate dehydrogenase (G6PD) deficiency: Use with caution in patients with G6PD deficiency; hemolysis may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Maintain adequate hydration to prevent crystalluria.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates: Sulfa antibiotics have been shown to displace bilirubin from protein binding sites which may potentially lead to hyperbilirubinemia and kernicterus in neonates and young infants; do not use in neonates; avoid use in infants &lt;2 months unless other options are not available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not for the treatment of group A beta-hemolytic streptococcal infections.</p></div>
<div class="block foc drugH1Div" id="F223759"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p></div>
<div class="block geq drugH1Div" id="F223745"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F2524726"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (sulfADIAZINE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $20.04</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F803230"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with at least 8 ounces of water and around-the-clock to promote less variation in peak and trough serum levels. Oral sodium bicarbonate may be used to alkalinize the urine of patients unable to maintain adequate fluid intake (in order to prevent crystalluria, azotemia, oliguria) (Lerner 1996).</p></div>
<div class="block admp drugH1Div" id="F52613887"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with at least 8 ounces of water and around-the-clock to promote less variation in peak and trough serum levels.</p></div>
<div class="block use drugH1Div" id="F223760"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">Treatment of toxoplasmosis encephalitis in combination with pyrimethamine and prophylaxis of rheumatic fever in patients with penicillin allergy.</p>
<p style="text-indent:-2em;margin-left:2em;">Although FDA approved for treatment of the following indications, use of sulfadiazine has been replaced by other agents: chancroid, trachoma, inclusion conjunctivitis, nocardiosis, urinary tract infection, malaria, acute otitis media, and meningitis (treatment and prophylaxis of meningococcal meningitis and treatment of <i>Haemophilus influenzae</i> meningitis).</p></div>
<div class="block mst drugH1Div" id="F223809"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">SulfADIAZINE may be confused with sulfaSALAzine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (when used in pregnancy at term) among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Sulfonamides, when used in neonates, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of kernicterus except sulfadiazine as adjunctive therapy with pyrimethamine as a treatment of congenital toxoplasmosis (weak recommendation; very low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F223797"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (minor), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F223754"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May diminish the therapeutic effect of Sulfonamide Antibiotics. Management: Avoid concurrent use of chloroprocaine and systemic sulfonamide-based antimicrobials whenever possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Sulfonamide Antibiotics may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Antibiotics may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: SulfADIAZINE may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methenamine: May enhance the adverse/toxic effect of Sulfonamide Antibiotics. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Sulfonamide Antibiotics may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and therapeutic doses of sulfonamides (eg, trimethoprim/sulfamethoxazole). Patients receiving prophylactic doses of trimethoprim/sulfamethoxazole and methotrexate should be carefully monitored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium P-Aminobenzoate: May diminish the therapeutic effect of Sulfonamide Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procaine: May diminish the therapeutic effect of Sulfonamide Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pyrimethamine: May enhance the adverse/toxic effect of Sulfonamide Antibiotics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Sulfonamide Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Sulfonamide Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Consider reducing the vitamin K antagonist dose by 10% to 20% prior to starting the sulfonamide antibiotic. Monitor INR closely to further guide dosing.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F223773"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Vitamin C or acidifying agents (cranberry juice) may cause crystalluria. Management: Avoid large quantities of vitamin C or acidifying agents (cranberry juice). </p></div>
<div class="block pri drugH1Div" id="F8774446"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Sulfadiazine crosses the placenta (Speert 1943).</p>
<p style="text-indent:0em;margin-top:2em;">A systematic review of 8 studies (860 pregnancies) and 10 case reports did not find a consistent pattern of adverse fetal or neonatal outcomes following in utero exposure to sulfadiazine. Exposures during the first trimester was limited. Jaundice was reported in some infants; however, data were too limited to calculate a risk of progression to kernicterus in the newborn (Yu 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of sulfadiazine may be altered; serum levels may be decreased during pregnancy (Reiter-Owona 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Sulfadiazine is recommended for use in pregnant patients to prevent <i>Toxoplasmosis gondii</i> infection of the fetus, and for the maternal treatment of <i>T. gondii</i> encephalitis (HHS [OI adult 2021]). Sulfadiazine is an alternative agent for the secondary prevention of rheumatic fever in pregnant patients; however, use is not recommended during the third trimester (AHA [Gerber 2009]).</p>
<p style="text-indent:0em;margin-top:2em;">Use with caution in patients with G6PD deficiency; hemolysis may occur. Due to the theoretical increased risk for hyperbilirubinemia and kernicterus, sulfadiazine is contraindicated by the manufacturer for use near term. Neonatal health care providers should be informed if maternal sulfonamide therapy is used near the time of delivery (HHS [OI adult 2021]).</p></div>
<div class="block brc drugH1Div" id="F8774449"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Sulfadiazine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Per the manufacturer, sulfadiazine is contraindicated while breastfeeding because sulfonamides cross into the milk and may cause kernicterus in the newborn. The World Health Organization recommends avoiding use in breastfeeding patients when possible, especially if the infant is premature or &lt;1 month of age. Breastfed infants should be monitored for side effects, such as bloody diarrhea, hemolysis, and jaundice; avoid if infant is G6PD deficient. In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora (WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F223766"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Supplemental leucovorin calcium should be administered to reverse symptoms or prevent problems due to folic acid deficiency.</p></div>
<div class="block mop drugH1Div" id="F12925088"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Perform culture and sensitivity testing prior to initiating therapy; frequent CBC and urinalysis during therapy; signs of serious blood disorders (sore throat, fever, pallor, purpura, dark urine, jaundice); CD4+ count in HIV-exposed/-positive patients treated for toxoplasmosis</p></div>
<div class="block pha drugH1Div" id="F223748"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferes with bacterial growth by inhibiting bacterial folic acid synthesis through competitive antagonism of PABA</p></div>
<div class="block phk drugH1Div" id="F223763"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Well absorbed </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Throughout body tissues and fluids including pleural, peritoneal, synovial, and ocular fluids; throughout total body water; readily diffused into CSF</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 38% to 48%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Via N-acetylation </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 10 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Within 3-6 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (43% to 60% as unchanged drug, 15% to 40% as metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038834"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Sulfadiazina vannier</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Sulphadiazine | Sulphadiazine sod</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Furp sulfadiazina | Neo sulfazina | Suladrin | Sulfazina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Sulfadiazin Streuli</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Sulfadiazina</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Limisulf</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Sulfadiazin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Sulfadiazina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Sulfadiazinum-heyl</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Sulphadiazine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Sulfadiazina</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Adiazin | Sulfadiasal | Sulfolex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Adiazine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Sulphadiazine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Adiazine | Sulfadiazina</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Sulphadiazine</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Sulphadiazine</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Sulfadiazina</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Diazine kimei</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Sulfadiazin | Sulfadiazin heyl</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Adiazine | Sulfadiazina reig jofre</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Sulfadiazin heyl | Sulfadiazine wockhardt</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Sulphadiazine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Sulphadiazine | Sulphazine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Sulfadiazin | Sulfadiazin Streuli | Sulfadiazina Ecobi</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Labdiazina | Sulfadiazina</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Sulfadiazin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Rediazine | Sulfazine-M | Sulphadiazine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Adiazine</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Sulfadiazina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Sulfadiazina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Sulphadiazine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8699959">
<a name="8699959"></a>Becker K, Jablonowski H, Häussinger D. Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. <i>Medicine (Baltimore)</i>. 1996;75(4):185-194. doi:10.1097/00005792-199607000-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/8699959/pubmed" id="8699959" target="_blank">8699959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15303450">
<a name="15303450"></a>Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/15303450/pubmed" id="15303450" target="_blank">15303450</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Microbial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Parasites – Toxoplasmosis (Toxoplasma infection): Resources for health professionals. <a href="https://www.cdc.gov/parasites/toxoplasmosis/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/toxoplasmosis/health_professionals/index.html</a>. Last reviewed May 26, 2020. Accessed August 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-876920">
<a name="876920"></a>Craft AW, Brocklebank JT, Jackson RH. Acute renal failure and hypoglycaemia due to sulphadiazine poisoning. <i>Postgrad Med J</i>. 1977;53(616):103-104. doi:10.1136/pgmj.53.616.103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/876920/pubmed" id="876920" target="_blank">876920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8949595">
<a name="8949595"></a>de Sequera P, Albalate M, Hernandez J, et al. Acute renal failure due to sulphadiazine crystalluria in AIDS patients. <i>Postgrad Med J</i>. 1996;72(851):557-558. doi:10.1136/pgmj.72.851.557<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/8949595/pubmed" id="8949595" target="_blank">8949595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19246689">
<a name="19246689"></a>Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. <i>Circulation</i>. 2009;119(11):1541-1551. doi:10.1161/CIRCULATIONAHA.109.191959<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/19246689/pubmed" id="19246689" target="_blank">19246689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26092827">
<a name="26092827"></a>Hogan JJ, Markowitz GS, Radhakrishnan J. Drug-induced glomerular disease: immune-mediated injury. <i>Clin J Am Soc Nephrol</i>. 2015;10(7):1300-1310. doi:10.2215/CJN.01910215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/26092827/pubmed" id="26092827" target="_blank">26092827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644481">
<a name="15644481"></a>Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in <i>Ann Pharmacother</i>. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/15644481/pubmed" id="15644481" target="_blank">15644481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27704057">
<a name="27704057"></a>Kabha M, Dekalo S, Barnes S, Mintz I, Matzkin H, Sofer M. Sulfadiazine-induced obstructive nephropathy presenting with upper urinary tract extravasation. <i>J Endourol Case Rep</i>. 2016;2(1):159-161. doi:10.1089/cren.2016.0093<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/27704057/pubmed" id="27704057" target="_blank">27704057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21546639">
<a name="21546639"></a>Khalili H, Soudbakhsh A, Talasaz AH. Severe hepatotoxicity and probable hepatorenal syndrome associated with sulfadiazine. <i>Am J Health Syst Pharm</i>. 2011;68(10):888-892. doi:10.2146/ajhp100516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/21546639/pubmed" id="21546639" target="_blank">21546639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8783685">
<a name="8783685"></a>Lerner PI. Nocardiosis. <i>Clin Infect Dis</i>. 1996;22(6):891-903. doi:10.1093/clinids/22.6.891<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/8783685/pubmed" id="8783685" target="_blank">8783685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1436353">
<a name="1436353"></a>Marques LP, Silva MT, Madeira EP, Santos OR. Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient. <i>Nephron</i>. 1992;62(3):361. doi:10.1159/000187075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/1436353/pubmed" id="1436353" target="_blank">1436353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23001098">
<a name="23001098"></a>McGettigan BD, Hew M, Phillips E, McLean-Tooke A. Sulphadiazine-induced renal stones in a 63-year-old HIV-infected man treated for toxoplasmosis. <i>BMJ Case Rep</i>. 2012;2012:bcr2012006638. doi:10.1136/bcr-2012-006638<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/23001098/pubmed" id="23001098" target="_blank">23001098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16511396">
<a name="16511396"></a>McLeod R, Khan AR, Noble GA, et al. Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. <i>Pediatr Infect Dis J</i>. 2006;25(3):270-272. doi:10.1097/01.inf.0000202070.59190.9a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/16511396/pubmed" id="16511396" target="_blank">16511396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. Key potentially inappropriate drugs in pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29661742">
<a name="29661742"></a>Monge-Ortega OP, Cabañas R, Fiandor A, et al. Overlap between DRESS syndrome and exanthema induced by sulfadiazine in a patient treated with sulfamethoxazole: utility of the lymphocyte transformation test for identification of the culprit drug. <i>J Investig Allergol Clin Immunol</i>. 2018;28(2):132-134. doi:10.18176/jiaci.0220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/29661742/pubmed" id="29661742" target="_blank">29661742</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Reiter-Owona I, Hlobil H, Enders M, et al. Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a case-control study. <i>Eur J Med Res</i>. 2020;25(1):59. doi:10.1186/s40001-020-00458-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/33228795/pubmed" id="33228795" target="_blank">33228795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15242722">
<a name="15242722"></a>Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/15242722/pubmed" id="15242722" target="_blank">15242722</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Speert H, "Placental Transmission of Sulfathiazole and Sulfadiazine and its Significance for Fetal Chemotherapy," <i>Am J Obstet Gynecol</i>, 1943, 45:200-7.</div>
</li>
<li>
<div class="reference">
                  Sulfadiazine [prescribing information]. Laurelton, NY: Epic Pharma LLC; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15373844">
<a name="15373844"></a>Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/15373844/pubmed" id="15373844" target="_blank">15373844</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines</a>. Accessed June 9, 2021.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Accessed August 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29261833">
<a name="29261833"></a>Velter C, Hotz C, Ingen-Housz-Oro S, Wolkenstein P, Fardet L. Stevens-Johnson syndrome during pregnancy: case report of a newborn treated with the culprit drug. <i>JAMA Dermatol</i>. 2018;154(2):224-225. doi:10.1001/jamadermatol.2017.4607<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/29261833/pubmed" id="29261833" target="_blank">29261833</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference">
                  Yu PA, Tran EL, Parker CM, et al. Safety of antimicrobials during pregnancy: a systematic review of antimicrobials considered for treatment and postexposure prophylaxis of plague. <i>Clin Infect Dis</i>. 2020;70(70)(suppl 1):S37-S50. doi:10.1093/cid/ciz1231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/32435799/pubmed" id="32435799" target="_blank">32435799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20413982">
<a name="20413982"></a>Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole. <i>Int Arch Allergy Immunol</i>. 2010;153(2):152-156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfadiazine-drug-information/abstract-text/20413982/pubmed" id="20413982" target="_blank">20413982</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9960 Version 217.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
